

# Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

<https://marketpublishers.com/r/BC8F7548654EN.html>

Date: March 2023

Pages: 350

Price: US\$ 2,699.00 (Single User License)

ID: BC8F7548654EN

## Abstracts

The biosimilar market in Europe size reached US\$ 9,841 Million in 2022. Looking forward, IMARC Group expects the market to reach US\$ 35,993 Million by 2028, exhibiting a growth rate (CAGR) of 20.41% during 2023-2028.

The European biosimilar market represents the most mature in the world and continues to rally momentum. This market is expected to grow robustly in the next five years, as a number blockbuster biologics are scheduled to lose patent protection in Europe.

Biosimilars are biotherapeutic products which are similar to already licensed reference biologics, in terms of quality, safety and efficiency. Biosimilar manufacturers wait till the patent of the reference product expires and then seek approval from the regulatory authorities in order to produce their biosimilar versions. These manufacturers use the state-of-the-art technology for comparing the characteristics, such as purity, chemical identity and bioactivity, of the proposed biosimilar to its reference product. In 2005, a science-based regulatory framework was established in the European Union (EU) for ensuring the production of high-quality biosimilars. Later in 2006, the European Medicines Agency (EMA) approved the first biosimilar medicine, Omnitrope. Since then, a number of biosimilars belonging to various therapeutic classes have been approved in Europe.

### Biosimilars Market in Europe: Drivers

Biosimilars are less expensive than their branded counterparts as they do not require extensive research and testing which saves both money and time; thereby lowering the costs. Moreover, they also have short marketing times as launching a biosimilar does not require extensive marketing as the safety and efficacy profile of their branded

counterparts have already been established.

Several blockbuster biologics are expected to lose their patent protection over the next 5 to 10 years. This expiration of patents and other intellectual property rights is expected to create huge opportunities for biosimilar manufacturers.

The European population is ageing with around one fifth of the total EU population above 65 years of age. There has resulted in a significant increase in the burden of lifestyle diseases in the region. The prevalence of diseases such as diabetes, autoimmune diseases, oncology, etc. has been increasing rapidly in Europe. This is also expected to propel the market growth during the next few years.

As a result of rising healthcare costs, governments across a number of European countries have formulated policies incentivising physicians, pharmacists and patients in favour of biosimilars over branded biologics.

#### Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the biosimilar market in Europe report, along with forecasts at the regional and country level from 2023-2028. Our report has categorized the market based on molecule, indication and manufacturing type.

#### Breakup by Country:

- Italy
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe

Country-wise, the market has been segmented into Italy, Germany, United Kingdom, France, Spain and Rest of Europe.

#### Breakup by Molecule:

- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim

Somatropin  
Rituximab  
Follitropin Alfa  
Adalimumab

The report has analysed the market on the basis of molecule. The market has been segmented into Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, etc.

Breakup by Indication:

Auto-Immune Diseases  
Blood Disorder  
Diabetes  
Oncology  
Growth Deficiency  
Female Infertility

The report has also analyzed the market on the basis of indication, covering oncology, autoimmune diseases, blood disorders, growth deficiency, diabetes, and female infertility.

Breakup by Manufacturing Type:

In-house Manufacturing  
Contract Manufacturing

On the basis of manufacturing type, the report has segmented the market into in-house manufacturing and contract manufacturing.

Some of the leading players operating in the European biosimilars market include:

Novartis  
Pfizer  
Teva  
Celltrion  
Samsung Bioepis  
Amgen  
Apotex

Ratiopharm  
Mylan  
Merck Sharp & Dohme  
Eli Lilly  
Accord Healthcare Ltd  
Boehringer Ingelheim  
Hexal Ag  
Stada Arzneimittel Ag

This report provides a deep insight into the European biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the European biosimilars market in any manner.

#### Key Questions Answered in This Report

1. What was the size of the biosimilar market in Europe in 2022?
2. What is the expected growth rate of the biosimilar market in Europe during 2023-2028?
3. What are the key factors driving the biosimilar market in Europe?
4. What has been the impact of COVID-19 on the biosimilar market in Europe?
5. What is the breakup of biosimilar market in Europe breakup based on the molecule?
6. What is the breakup of biosimilar market in Europe based on the indication?
7. What is the breakup of biosimilar market in Europe based on the manufacturing type?
8. What are the key regions in the biosimilar market in Europe?
9. Who are the key players/companies in the biosimilar market in Europe?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 EUROPE BIOSIMILARS MARKET – INTRODUCTION**

- 4.1 Overview
- 4.2 WHO and EMA Terminology on Biosimilars
- 4.3 Biosimilars and Generics
- 4.4 Biosimilars and Branded Biological Products

### **5 EUROPE BIOSIMILARS MARKET**

- 5.1 Market Overview
- 5.2 Historical and Current Market Trends
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Country
- 5.5 Market Breakup by Molecule
- 5.6 Market Breakup by Indication
- 5.7 Market Breakup by Manufacturing Type
- 5.8 Patent Landscape
- 5.9 Market Forecast

### **6 MARKET BREAKUP BY COUNTRY**

## 6.1 Italy

6.1.1 Market Performance

6.1.2 Key Players and Biosimilars

6.1.3 Market Forecast

## 6.2 Germany

6.2.1 Market Performance

6.2.2 Key Players and Biosimilars

6.2.3 Market Forecast

## 6.3 France

6.3.1 Market Performance

6.3.2 Key Players and Biosimilars

6.3.3 Market Forecast

## 6.4 United Kingdom

6.4.1 Market Performance

6.4.2 Key Players and Biosimilars

6.4.3 Market Forecast

## 6.5 Spain

6.5.1 Market Performance

6.5.2 Key Players and Biosimilars

6.5.3 Market Forecast

## 6.6 Rest of Europe

6.6.1 Market Performance

6.6.2 Market Forecast

## 7 MARKET BREAKUP BY MOLECULE

7.1 Infliximab

7.2 Insulin Glargine

7.3 Epoetin Alfa

7.4 Etanercept

7.5 Filgrastim

7.6 Somatropin

7.7 Rituximab

7.8 Follitropin Alfa

7.9 Adalimumab

## 8 MARKET BREAKUP BY MANUFACTURING TYPE

8.1 In-house Manufacturing

- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Contract Manufacturing
  - 8.2.1 Market Trends
  - 8.2.2 Market Forecast

## **9 MARKET BREAKUP BY INDICATION**

- 9.1 Auto-Immune Diseases
- 9.2 Blood Disorder
- 9.3 Diabetes
- 9.4 Oncology
- 9.5 Growth Deficiency
- 9.6 Female Infertility

## **10 EUROPEAN BIOSIMILAR MARKET: SWOT ANALYSIS**

- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats

## **11 EUROPEAN BIOSIMILAR MARKET: VALUE CHAIN ANALYSIS**

- 11.1 Characterizing the Existing Innovator Drug
- 11.2 Research and Development
  - 11.2.1 Characterization of Biosimilars
  - 11.2.2 Developing a Unique Cell Line
- 11.3 Product Development
  - 11.3.1 Pre-Testing
  - 11.3.2 Intermediary Clinical Testing (PK/PD)
  - 11.3.3 Confirmatory Clinical Phase-III
- 11.4 Final Product Formulation
- 11.5 Marketing and Distribution

## **12 PORTER'S FIVE FORCES ANALYSIS**

- 12.1 Overview

- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes

## **13 PRICE ANALYSIS**

- 13.1 Key Price Indicators
- 13.2 Price Trends

## **14 REQUIREMENTS FOR SETTING UP A GENERIC DRUG MANUFACTURING PLANT**

- 14.1 Manufacturing Process
- 14.2 Raw Material Requirements
- 14.3 Raw Material Pictures
- 14.4 Land and Construction Requirements
- 14.5 Machinery and Infrastructure Requirements
- 14.6 Machinery Pictures
- 14.7 Plant Layout
- 14.8 Packaging Requirements
- 14.9 Utility Requirements
- 14.10 Manpower Requirements

## **15 COMPETITIVE LANDSCAPE**

- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
  - 15.3.1 Novartis
  - 15.3.2 Pfizer
  - 15.3.3 Teva
  - 15.3.4 Celltrion
  - 15.3.5 Merck Sharp & Dohme
  - 15.3.6 Samsung Bioepis
  - 15.3.7 Eli Lilly
  - 15.3.8 Accord Healthcare Ltd.
  - 15.3.9 Amgen



15.3.10 Boehringer Ingelheim

15.3.11 Hexal Ag

15.3.12 Apotex

15.3.13 Stada Arzneimittel Ag

15.3.14 Ratiopharm

15.3.15 Mylan

## List Of Tables

### LIST OF TABLES

Table 1: Europe: Sales and Patent Expiry of Blockbuster Biological Drugs (in Million US\$)

Table 2: Biosimilar vs. Innovators Drug Development

Table 3: Biosimilar vs. Biologics Manufacturing

Table 4: Europe: Biosimilar Market: Key Industry Highlights, 2022 and 2028

Table 5: Europe: Biosimilar Market: Patent Landscape

Table 6: Europe: Biosimilar Market: Price Comparison Between Biosimilar and Originator Drugs

Table 7: Europe: Biosimilar Market Forecast: Breakup by Region (in Million US\$), 2023-2028

Table 8: Europe: Biosimilar Market: Key Players and Biosimilars

Table 9: Italy: Biosimilar Market: Key Players and Biosimilars

Table 10: Germany: Biosimilar Market: Key Players and Biosimilars

Table 11: France: Biosimilar Market: Key Players and Biosimilars

Table 12: United Kingdom: Biosimilar Market: Key Players and Biosimilars

Table 13: Spain: Biosimilar Market: Key Players and Biosimilars

Table 14: Europe: Rituximab: Brand & Biosimilar Market Overview

Table 15: Europe: Infliximab: Brand & Biosimilar Market Overview

Table 16: Europe: Insulin Glargine: Brand & Biosimilar Market Overview

Table 17: Europe: Epoetin Alfa: Brand & Biosimilar Market Overview

Table 18: Europe: Filgrastim: Brand & Biosimilar Market Overview

Table 19: Europe: Somatropin: Brand & Biosimilar Market Overview

Table 20: Europe: Etanercept: Brand & Biosimilar Market Overview

Table 21: Europe: Follitropin Alfa: Brand & Biosimilar Market Overview

Table 22: Europe: Biosimilar Market Forecast: Breakup by Manufacturing Type (in Million US\$), 2023-2028

Table 23: Europe: Biosimilar Market Forecast: Breakup by Indication (in Million US\$), 2023-2028

Table 24: Biosimilar Manufacturing Plant: Raw Material Requirements

Table 25: Biosimilar Manufacturing Plant: Land and Construction Requirements

Table 26: Biosimilar Manufacturing Plant: Machinery Requirements

Table 27: Biosimilar Manufacturing Plant: Manpower Requirements

Table 28: Europe: Biosimilar Market: Competitive Structure

Table 29: Europe: Biosimilar Market: Key Players

## List Of Figures

### LIST OF FIGURES

- Figure 1: Europe: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 2: Europe: Biosimilar Market: Breakup by Molecule (in %), 2022
- Figure 3: Europe: Biosimilar Market: Breakup by Manufacturing Type (in %), 2022
- Figure 4: Europe: Biosimilar Market: Breakup by Indication (in %), 2022
- Figure 5: Europe: Biosimilar Market: Breakup by Country (in %), 2022
- Figure 6: Europe: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 7: Italy: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 8: Italy: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 9: Germany: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 10: Germany: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 11: France: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 12: France: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 13: United Kingdom: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 14: United Kingdom: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 15: Spain: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 16: Spain: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 17: Rest of Europe: Biosimilar Market: Sales Value (in Million US\$), 2017-2022
- Figure 18: Rest of Europe: Biosimilar Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 19: Europe: Rituximab Biosimilar Market: Sales Value (in Million US\$), 2017
- Figure 20: Europe: Infliximab Biosimilar Market: Sales Value (in Million US\$), 2015 - 2017
- Figure 21: Europe: Insulin Glargine Biosimilar Market: Sales Value (in Million US\$), 2016 & 2017
- Figure 22: Europe: Epoetin Alfa Biosimilar Market: Sales Value (in Million US\$), 2014 - 2017
- Figure 23: Europe: Filgrastim Biosimilar Market: Sales Value (in Million US\$), 2014 - 2017
- Figure 24: Europe: Somatropin Biosimilar Market: Sales Value (in Million US\$), 2014 - 2017
- Figure 25: Europe: Etanercept Biosimilar Market: Sales Value (in Million US\$), 2016 & 2017
- Figure 26: Europe: Follitropin Alfa Biosimilar Market: Sales Value (in Million US\$), 2015

- 2017

Figure 27: Europe: Adalimumab Biosimilar Market: Sales Value (in Million US\$), 2018

Figure 28: Europe: Biosimilar Market (In-House Manufacturing): Sales Value (in Million US\$), 2017 & 2022

Figure 29: Europe: Biosimilar Market Forecast (In-House Manufacturing): Sales Value (in Million US\$), 2023-2028

Figure 30: Europe: Biosimilar Market (Contract Manufacturing): Sales Value (in Million US\$), 2017 & 2022

Figure 31: Europe: Biosimilar Market Forecast (Contract Manufacturing): Sales Value (in Million US\$), 2023-2028

Figure 32: Europe: Biosimilar Market (Autoimmune Diseases): Sales Value (in Million US\$), 2017 & 2022

Figure 33: Europe: Biosimilar Market Forecast (Autoimmune Diseases): Sales Value (in Million US\$), 2023-2028

Figure 34: Europe: Biosimilar Market (Blood Disorders): Sales Value (in Million US\$), 2017 & 2022

Figure 35: Europe: Biosimilar Market Forecast (Blood Disorders): Sales Value (in Million US\$), 2023-2028

Figure 36: Europe: Biosimilar Market (Diabetes): Sales Value (in Million US\$), 2017 & 2022

Figure 37: Europe: Biosimilar Market Forecast (Diabetes): Sales Value (in Million US\$), 2023-2028

Figure 38: Europe: Biosimilar Market (Oncology): Sales Value (in Million US\$), 2017 & 2022

Figure 39: Europe: Biosimilar Market Forecast (Oncology): Sales Value (in Million US\$), 2023-2028

Figure 40: Europe: Biosimilar Market (Growth Deficiency): Sales Value (in Million US\$), 2017 & 2022

Figure 41: Europe: Biosimilar Market Forecast (Growth Deficiency): Sales Value (in Million US\$), 2023-2028

Figure 42: Europe: Biosimilar Market (Female Infertility): Sales Value (in Million US\$), 2017 & 2022

Figure 43: Europe: Biosimilar Market Forecast (Female Infertility): Sales Value (in Million US\$), 2023-2028

Figure 44: Europe: Biosimilar Industry: SWOT Analysis

Figure 45: Europe: Biosimilar Industry: Value Chain Analysis

Figure 46: Europe: Biosimilar Industry: Porter's Five Forces Analysis

Figure 47: Biosimilar Manufacturing: Detailed Process Flow

## I would like to order

Product name: Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Product link: <https://marketpublishers.com/r/BC8F7548654EN.html>

Price: US\$ 2,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC8F7548654EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

